Dynavax Technologies Corp. DVAX

NAS: DVAX | ISIN: US2681582019 9/02/2026

15,50 USD (0,00%)

(0,00%) 9/02/2026

Grafiek Dynavax Technologies Corp.

Grafiek Dynavax Technologies Corp.

1 dag1d 0,00%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 42,86%
6 maanden6m 65,60%
1 jaar1j 11,75%
5 jaar5j 51,81%

Dynavax Technologies Corp. in het nieuws

Toon enkel gratis nieuws

24 december 2025 · Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline · Persbericht

19 november 2025 · Dynavax to Participate at the 8th Annual Evercore Healthcare Conference · Persbericht

5 november 2025 · Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program · Persbericht

5 november 2025 · Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program · Persbericht

22 oktober 2025 · Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 · Persbericht

21 oktober 2025 · Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial · Persbericht

27 augustus 2025 · Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference · Persbericht

21 augustus 2025 · Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile · Persbericht

7 augustus 2025 · Dynavax Reports Second Quarter 2025 Financial Results · Persbericht

29 juli 2025 · Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 · Persbericht

Profiel Dynavax Technologies Corp.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.dynavax.com

Hoofdzetel: Emeryville, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe